Sugi Predict

Sugi Predict / Compounds / SCHEMBL16742433

SCHEMBL16742433

SCHEMBL16742433

CC(C)(C)OC(=O)N1Cc2c(c3ccccc3n2Cc2ccc(F)cc2)C[C@H]1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 2/20 0.52
▸ HDAC6 Q9UBN7 8/20 0.51
▸ HDAC1 Q13547 5/20 0.51
▸ HDAC8 Q9BY41 3/20 0.44
▸ CHRM2 P08172 1/20 0.43
▸ HTR1A P08908 1/20 0.43
▸ ADRA2A P08913 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ DRD1 P21728 1/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ SLC6A4 P31645 1/20 0.43
▸ ADRA1A P35348 1/20 0.43
▸ OPRM1 P35372 1/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ TBXA2R P21731 3/20 0.43
▸ PTGDR Q13258 3/20 0.43
▸ PTGDR2 Q9Y5Y4 3/20 0.43
▸ HDAC3 O15379 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18044835 1.00 ENPP2 (0.52) ENPP2HDAC6HDAC1HDAC8CHRM2
SCHEMBL16742434 1.00 ENPP2 (0.52) ENPP2HDAC6HDAC1HDAC8CHRM2
SCHEMBL30425869 1.00 ENPP2 (0.52) ENPP2HDAC6HDAC1HDAC8CHRM2
SCHEMBL16750193 0.92 ENPP2 (0.49) ENPP2HDAC6HDAC1HDAC8HDAC3
SCHEMBL16750309 0.91 HDAC6 (0.50) ENPP2HDAC6HDAC1HDAC8HDAC3
SCHEMBL16750333 0.87 HDAC6 (0.47) ENPP2HDAC6HDAC1HDAC8HDAC3
SCHEMBL18070799 0.87 ENPP2 (0.50) ENPP2HDAC6HDAC1HDAC8TBXA2R
SCHEMBL16750311 0.87 ENPP2 (0.50) ENPP2HDAC6HDAC1HDAC8TBXA2R
SCHEMBL18044815 0.87 HDAC6 (0.48) ENPP2HDAC6HDAC1HDAC8CHRM2
SCHEMBL16750266 0.87 HDAC6 (0.48) ENPP2HDAC6HDAC1HDAC8CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12458627-B2 Autotaxin inhibitors and uses thereof DF 2024 IP ACQUISITION, LLC (US) 2025-11-04 — — US disclosed
CN-116059203-A Autotaxin inhibitors and uses thereof 赛博治疗有限责任公司 2023-05-05 — — CN disclosed
EP-4026549-A1 AUTOTAXIN INHIBITORS AND USES THEREOF Sabre Therapeutics LLC (US) 2022-07-13 — — EP disclosed
EP-3302490-B1 AUTOTAXIN INHIBITORS AND USES THEREOF SABRE THERAPEUTICS LLC (US) 2022-04-13 — — EP disclosed
US-20200215034-A1 AUTOTAXIN INHIBITORS AND USES THEREOF INSOLVENCY SERVICES GROUP, INC. 2020-07-09 — — US disclosed
US-10632104-B2 Autotaxin inhibitors and uses thereof SABRE THERAPEUTICS LLC (US) 2020-04-28 — — US disclosed
US-20180162859-A1 TETRACYCLIC AUTOTAXIN INHIBITORS ATXCO, INC. 2018-06-14 — — US disclosed
US-20180162859-A1 TETRACYCLIC AUTOTAXIN INHIBITORS ATXCO, INC. 2018-06-14 — — US disclosed
US-20180162859-A1 TETRACYCLIC AUTOTAXIN INHIBITORS ATXCO, INC. 2018-06-14 — — US disclosed
US-20180147185-A1 AUTOTAXIN INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2018-05-31 — — US disclosed
EP-3071569-A1 TETRACYCLIC AUTOTAXIN INHIBITORS Pharmakea Inc. (US) 2016-09-28 — — EP disclosed
US-20160264575-A1 TETRACYCLIC AUTOTAXIN INHIBITORS DF 2024 IP ACQUISITION, LLC 2016-09-15 — — US disclosed
US-20160264575-A1 TETRACYCLIC AUTOTAXIN INHIBITORS DF 2024 IP ACQUISITION, LLC 2016-09-15 — — US disclosed
US-20160264575-A1 TETRACYCLIC AUTOTAXIN INHIBITORS DF 2024 IP ACQUISITION, LLC 2016-09-15 — — US disclosed
WO-2016028686-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS PHARMAKEA, INC. (US) 2016-02-25 — — WO disclosed
US-9051320-B1 Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor PHARMAKEA, INC. (US) 2015-06-09 — — US disclosed
US-9051320-B1 Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor PHARMAKEA, INC. (US) 2015-06-09 — — US disclosed
US-9051320-B1 Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor PHARMAKEA, INC. (US) 2015-06-09 — — US disclosed
WO-2015077502-A1 TETRACYCLIC AUTOTAXIN INHIBITORS PHARMAKEA, INC. (US) 2015-05-28 — — WO disclosed
WO-2015077502-A1 TETRACYCLIC AUTOTAXIN INHIBITORS PHARMAKEA, INC. (US) 2015-05-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180147185-A1 AUTOTAXIN INHIBITORS AND USES THEREOF ENPP2, SERPINB1, RNASE1 ENPP2 1/4885HDAC6 448/4885HDAC1 2293/4885
US-20180162859-A1 TETRACYCLIC AUTOTAXIN INHIBITORS ENPP2, SERPINB1, UACA ENPP2 1/4885HDAC6 195/4885HDAC1 1017/4885
US-10632104-B2 Autotaxin inhibitors and uses thereof ENPP2, SERPINB1, RNASE1 ENPP2 1/4885HDAC6 448/4885HDAC1 2293/4885
US-20200215034-A1 AUTOTAXIN INHIBITORS AND USES THEREOF ENPP2, SERPINB1, RNASE1 ENPP2 1/4885HDAC6 448/4885HDAC1 2293/4885
US-12458627-B2 Autotaxin inhibitors and uses thereof ENPP2, SERPINB1, RNASE1 ENPP2 1/4885HDAC6 448/4885HDAC1 2293/4885
US-20160264575-A1 TETRACYCLIC AUTOTAXIN INHIBITORS ENPP2, SERPINB1, UACA ENPP2 1/4885HDAC6 195/4885HDAC1 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback